Abstract
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Current Pharmaceutical Design
Title:The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Volume: 25 Issue: 8
Author(s): Jiayuan Qu, Mohammad Amjad Kamal and Chengfu Yuan*
Affiliation:
- Department of Biochemistry, China Three Gorges University, Yichang 443002,China
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Abstract:
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Export Options
About this article
Cite this article as:
Qu Jiayuan, Kamal Amjad Mohammad and Yuan Chengfu*, The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer , Current Pharmaceutical Design 2019; 25 (8) . https://dx.doi.org/10.2174/1381612825666190404122154
DOI https://dx.doi.org/10.2174/1381612825666190404122154 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design Radiolabeled Peptides and Proteins in Cancer Therapy
Protein & Peptide Letters Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
Current Drug Therapy Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology